{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:34:36Z","timestamp":1788554076263,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Volumetric Absorptive Microsampling (VAMS) is a useful tool for therapeutic drug monitoring (TDM) of oral targeted anticancer agents. VAMS aims to improve safety and efficacy by enabling at-home blood sample collection by patients. This study aimed to develop and validate an ultra-high performance liquid chromatography\u2013tandem mass spectrometry method for the quantitative determination of abiraterone, alectinib, cabozantinib, imatinib, olaparib, sunitinib, and the metabolites, \u0394(4)-abiraterone (D4A), alectinib-M4, imatinib-M1, and <jats:italic toggle=\"yes\">N<\/jats:italic>-desethyl sunitinib, in dried whole blood samples using VAMS to support TDM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>After the collection of 10 \u03bcL of whole blood sample using the VAMS device, the analytes were extracted from the tip using methanol with shaking, evaporated, and reconstituted in acetonitrile:0.1 mol\/L ammonium hydroxide in water (1:1, vol\/vol). The extracts were then analyzed using ultra-high performance liquid chromatography\u2013tandem mass spectrometry. Validation experiments based on the ICH M10 guideline were carried out, and stability was evaluated under shipping and storage conditions. VAMS specimens were collected in the outpatient clinic to demonstrate the applicability of the assay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The validated range of the method was considered accurate and precise for all analytes. Accordingly, the validation experiments met the relevant requirements, except for cross-analyte interference. Based on the stability data, shipment can be performed at room temperature within 14 days after sample collection and the VAMS specimen can be stored up to 9 months at \u221220 and \u221270\u00b0C. Samples from 59 patients were collected at the hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The developed method could be used to successfully quantify the concentrations of abiraterone, D4A, alectinib, alectinib-M4, cabozantinib, imatinib, imatinib-M1, olaparib, sunitinib, and <jats:italic toggle=\"yes\">N<\/jats:italic>-desethyl sunitinib within the validated range using VAMS. Therefore, the method can be used to estimate the dried whole blood-to-plasma ratios for TDM in the clinic.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001175","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T05:05:13Z","timestamp":1707282313000},"page":"494-502","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-9261","authenticated-orcid":false,"given":"Marinda","family":"Meertens","sequence":"first","affiliation":[{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands;"},{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands;"},{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands; and"},{"name":"Department of Pharmacology, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","article-title":"Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study","volume":"33","author":"Groenland","year":"2022","journal-title":"Ann Oncol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bcp.15674","article-title":"Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir\/velpatasvir: a case report","volume":"89","author":"Monribot","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-022-04437-z","article-title":"Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature","volume":"90","author":"van Berge Henegouwen","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1758835918818347","DOI":"10.1177\/1758835918818347","article-title":"Clinically relevant drug interactions with multikinase inhibitors: a review","volume":"11","author":"Hussaarts","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"R7-20250603","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3986","article-title":"Analytical challenges in quantifying abiraterone with LC-MS\/MS in human plasma","volume":"31","author":"Benoist","year":"2017","journal-title":"Biomed Chromatogr"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2019.01.001","article-title":"Development and validation of an UPLC-MS\/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology","volume":"1106\u20131107","author":"van Nuland","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"821807","DOI":"10.3389\/fonc.2022.821807","article-title":"Therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples","volume":"12","author":"Verougstraete","year":"2022","journal-title":"Front Oncol"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.1021\/ac5022562","article-title":"Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis","volume":"86","author":"Denniff","year":"2014","journal-title":"Anal Chem"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.aca.2015.04.056","article-title":"Does volumetric absorptive microsampling eliminate the hematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study","volume":"881","author":"De Kesel","year":"2015","journal-title":"Anal Chim Acta"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4155\/bio.11.220","article-title":"The effect of hematocrit and punch location on assay bias during quantitative bioanalysis of dried blood spot samples","volume":"3","author":"O'Mara","year":"2011","journal-title":"Bioanalysis"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.4155\/bio-2017-0167","article-title":"Volumetric absorptive microsampling combined with impact-assisted extraction for hematocrit effect free assays","volume":"9","author":"Youhnovski","year":"2017","journal-title":"Bioanalysis"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4155\/bio.14.310","article-title":"A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated blood hematocrit","volume":"7","author":"Spooner","year":"2015","journal-title":"Bioanalysis"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4155\/bio-2015-0028","article-title":"Evaluation of sample extraction methods for minimizing hematocrit effect on whole blood analysis with volumetric absorptive microsampling","volume":"9","author":"Ye","year":"2017","journal-title":"Bioanalysis"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jpba.2017.07.029","article-title":"Volumetric absorptive microsampling: current advances and applications","volume":"147","author":"Kok","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jpba.2018.04.001","article-title":"Extractability-mediated stability bias and hematocrit impact: high extraction recovery is critical to feasibility of volumetric adsorptive microsampling (VAMS) in regulated bioanalysis","volume":"156","author":"Xie","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"114623","DOI":"10.1016\/j.jpba.2022.114623","article-title":"Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio","volume":"211","author":"Zimmermann","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"114418","DOI":"10.1016\/j.jpba.2021.114418","article-title":"Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors","volume":"207","author":"Verougstraete","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"115311","DOI":"10.1016\/j.jpba.2023.115311","article-title":"Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib","volume":"228","author":"Zimmermann","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1515\/cclm-2020-1180","article-title":"Self-sampling at home using volumetric absorptive microsampling: coupling analytical evaluation to volunteers' perception in the context of a large scale study","volume":"59","author":"Van Uytfanghe","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"115033","DOI":"10.1016\/j.jpba.2022.115033","article-title":"Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS","volume":"221","author":"Opitz","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchromb.2018.11.030","article-title":"Validation and clinical application of an LC-MS\/MS method for the quantification of everolimus using volumetric absorptive microsampling","volume":"1104","author":"Verheijen","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"883","DOI":"10.4155\/bio-2020-0062","article-title":"Novel LC-MS\/MS method for the determination of selumetinib (AZD6244) in whole blood collected with volumetric absorptive microsampling","volume":"12","author":"Voggu","year":"2020","journal-title":"Bioanalysis"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2147\/DDDT.S286409","article-title":"Volumetric absorptive microsampling as a new biosampling tool for monitoring of tamoxifen, endoxifen, 4-OH tamoxifen and N-desmethyltamoxifen in breast cancer patients","volume":"15","author":"Maggadani","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"115108","DOI":"10.1016\/j.jpba.2022.115108","article-title":"Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: method development and clinical application in patients with chronic myeloid leukemia","volume":"222","author":"Kr\u00fctzmann","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical Toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"e4623","DOI":"10.1002\/bmc.4623","article-title":"Bioanalytical LC-MS\/MS validation of therapeutic drug monitoring assays in oncology","volume":"34","author":"van Nuland","year":"2020","journal-title":"Biomed Chromatogr"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"121925","DOI":"10.1016\/j.jchromb.2019.121925","article-title":"Development and validation of an integrated LC-MS\/MS assay for therapeutic drug monitoring of five PARP-inhibitors","volume":"1138","author":"Bruin","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/FTD.0000000000000349","article-title":"Quantification of 11 therapeutic kinase inhibitors in human plasma for therapeutic drug monitoring using liquid chromatography coupled with tandem mass spectrometry","volume":"38","author":"Herbrink","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jpba.2019.06.034","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma","volume":"174","author":"Janssen","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0076-6879(94)31040-8","article-title":"Hydroxylation and dealkylation reactions catalyzed by hemoglobin","volume":"231","author":"Mieyal","year":"1994","journal-title":"Methods Enzymol"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0006-2952(92)90279-R","article-title":"Enzymic N-demethylation reaction catalysed by red blood cell cytosol","volume":"43","author":"Stecca","year":"1992","journal-title":"Biochem Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:14:23Z","timestamp":1748970863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001175","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"2023-10-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}